Updates New Drugs Working Group MDR Working Group

Updates New Drugs Working Group & MDR Working Group Elizabeth Gardiner, TB Alliance Introducing New Tools & Approaches (INAT) - Berlin November 12, 2010

New Drug Working Group �Co-Chairs: Mel Spigelman & Bill Bishai �Members: 140+ including pharmaceutical companies, TB Alliance, TAG, Community Representative (Zimbabwe), BMGF �Subgroups on Clinical Trial Capacity, Biology Targets, New Candidates, Knowledge & Tools �Focus: R&D information sharing �Website with pipeline, blog, videos �Future: introduction of new drugs

Linkage with INAT �For WGND � Information about INAT � Link to INAT website, slides about what INAT is � Guidance � Who/where is the TB drug market � What patients/countries want � How can products be used � What dose works for uptake � Help Community Representative deliver the right message to the audience �For INAT � Useful pipeline for INAT � Go-to for scientific information on new drugs � Other?

MDR Working Group �Chair: Ahmer Khan, Indus Hospital �Members: PIH, WHO/SEARO, WHO/GVA, Community Representatives (Nigeria & India), Union, BMGF, Resist-TB, USAID, Eli Lily, PATH � Subgroups on Research, Infection Control & Prevention, Drug Management, Diagnostics �Overseeing & providing guidance on MDR issues including subgroup topics, GLI, compassionate use, etc.

Role for INAT �Should be grounded in framework of RTF �Need for coordination more than encouragement �Wants INAT to �track/disseminate info on all related new tools activities across Partnership, Department, & TDR, donor-funded activities (e. g. STREAM study, LPA studies, Gen. Expert availability) �identify sources of information on X, Y & Z (e. g. diagnostics, Resist-TB, TMC 207) �Advocate for new tools but through existing structures